Who are Egaten's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amvuttra, Vyndaqel, Vyndaqel, Vyndaqel, Vyndaqel, Onpattro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/triclabendazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Egaten — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Egaten (TRICLABENDAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthelmintic [EPC]. Area: Infectious Disease.

marketed Anthelmintic [EPC] Transthyretin Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Egaten (TRICLABENDAZOLE) — Novartis. Egaten works by binding to and inhibiting the enzyme responsible for the parasite's survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Egaten TARGET	TRICLABENDAZOLE	Novartis	marketed	Anthelmintic [EPC]	Transthyretin	2019-01-01
Amvuttra	VUTRISIRAN	Alnylam Pharmaceuticals	marketed	Small Interfering RNA	transthyretin (TTR) mRNA	2022-01-01
Vyndaqel	tafamidis-test	Foldrx Pharms	marketed	tafamidis	Transthyretin	2019-01-01
Vyndaqel	Tafamidis	Foldrx Pharms	marketed	tafamidis	Transthyretin	2019-01-01
Vyndaqel	tafamidis	Foldrx Pharms	marketed	tafamidis	Transthyretin	2019-01-01
Vyndaqel	Tafamidis Meglumine	Foldrx Pharms	marketed	Transthyretin stabilizer	Transthyretin (TTR)	2019-01-01
Onpattro	PATISIRAN SODIUM	Alnylam Pharmaceuticals	marketed	Small Interfering RNA	transthyretin (TTR) mRNA	2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-08-31 — Vyndaqel · 9770441 · US

Sponsor landscape (Anthelmintic [EPC] class)

· 2 drugs in this class
Impax Labs Inc · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Egaten — Competitive Intelligence Brief. https://druglandscape.com/ci/triclabendazole. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing